Physician profile
David Simon
NPI 1912979279
$3,370.86
in general payments reported to CMS, 2019-2025
36 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $254 · 2021: $657 · 2022: $851 · 2023: $658 · 2024: $275 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.13 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.40 | 2020-2025 | Ubrelvy, Vraylar |
| Supernus Pharmaceuticals, INC. | $278.13 | 2022-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $267.13 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $259.40 | 2019-2023 | Xtampza |
| Pfizer INC. | $230.73 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.66 | 2019-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $194.07 | 2022-2023 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $176.29 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $170.64 | 2019-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $135.88 | 2019-2023 | Belsomra, Steglatro |
| Eisai INC. | $101.02 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $95.70 | 2022-2023 | Seglentis, Livalo |
| Biohaven Pharmaceutical Holding Company Ltd. | $72.83 | 2022 | |
| Orexo US, INC. | $72.62 | 2020-2022 | |
| Exact Sciences Corporation | $65.40 | 2023-2025 | Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $62.86 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.74 | 2024-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $58.53 | 2023-2024 | Quviviq |
| Glaxosmithkline, LLC. | $53.34 | 2022-2025 | Trelegy Ellipta |
| Allergan, INC. | $45.56 | 2020 | |
| Amgen INC. | $35.70 | 2019-2024 | Repatha |
| Adlon Therapeutics L.P. | $31.89 | 2021 | |
| Lilly USA, LLC | $29.83 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.79 | 2023 | Stiolto Respimat |
| Otsuka America Pharmaceutical, INC. | $23.45 | 2022 | |
| Abbott Laboratories | $21.89 | 2023 | Freestyle Libre 2 |
| Forte Bio-Pharma LLC | $19.77 | 2024 | Prolate, Nalocet |
| Tonix Medicines, INC. | $19.61 | 2025 | Tonmya |
| E.R. Squibb & Sons, L.L.C. | $17.96 | 2021 | |
| Amarin Pharma, INC. | $15.96 | 2019 | |
| Gilead Sciences, INC. | $14.56 | 2019 | |
| Currax Pharmaceuticals LLC | $13.22 | 2022 | |
| Biodelivery Sciences International, INC. | $12.00 | 2020 | |
| Almatica Pharma LLC | $11.69 | 2022 | |
| Axsome Therapeutics, INC. | $9.62 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.